| Haytham Eleissawy, PHARMD | |
|
1700 Larkin Ave, Elgin, IL 60123-5947 | |
| (847) 695-1158 | |
| Not Available |
| Full Name | Haytham Eleissawy |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 1700 Larkin Ave, Elgin, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205448776 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 051300615 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Haytham Eleissawy, PHARMD 1700 Larkin Ave, Elgin, IL 60123-5947 Ph: () - | Haytham Eleissawy, PHARMD 1700 Larkin Ave, Elgin, IL 60123-5947 Ph: (847) 695-1158 |
News Archive
A gene called KRAS is one of the most commonly mutated genes in all human cancers, and targeted drugs that inhibit the protein expressed by mutated KRAS have shown promising results in clinical trials, with potential approvals by the U.S. Food and Drug Administration anticipated later this year.
Admedus today announced it has received FDA clearance to market CardioCel in the US. CardioCel is the group's lead regenerative tissue product to repair and treat a range of cardiovascular and vascular defects. The Company will now look to complement its existing product launch in Europe with preparation for initial sales in the US.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that in the follow-up portion of its Phase 2 clinical trial in patients with diabetic foot ulcers, the percentage of patients treated with the therapeutic dose of DSC127 with complete healing at 24 weeks following trial enrollment was 73% in the intent-to-treat population and 85% in the per-protocol population, a difference of 27 and 33 percentage points, respectively, compared with patients treated with placebo/standard of care.
NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.
› Verified 1 days ago
Jennifer Getzelman, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1700 Larkin Ave, Elgin, IL 60123 Phone: 847-695-1158 | |
Donald Lellish, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 815 N. Randall Rd, Elgin, IL 60123 Phone: 847-717-6510 | |
Carol Cassidy Novak, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1700 Larkin Ave, Elgin, IL 60123 Phone: 847-695-1158 | |
Kirstie Lynn Forst, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2517 Emily Ln, Elgin, IL 60124 Phone: 630-550-2600 | |
Dr. Emlo Bebo, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1100 S Randall Rd, Elgin, IL 60123 Phone: 847-468-9696 Fax: 847-468-5077 | |
Dr. Amanda Rose Pacholok, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 815 Summit St, Elgin, IL 60120 Phone: 847-695-5847 | |
Shreya Patel, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 815 S Randall Rd, Elgin, IL 60123 Phone: 914-482-0631 |